MRSA Drugs Market: Unhygienic Conditions Resulting in Infection Results in Drug Sales, says TMR

The global MRSA drugs market is chiefly driven by rising instances of the infection resulting from people working in unhygienic conditions, finds a study by Transparency Market Research based on a recent report. The report, titled, “MRSA Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025,” paints a comprehensive picture of this market which include a discussion of its growth drivers, prominent businesses, regional outreach, treatment options, and others.

Methicillin-resistant Staphylococcus aureus (MRSA) is a skin infection caused by a bacterium. Its symptoms vary, depending upon the infected area. While at times it simply results in minor skin infection, at other times is can bring about more serious consequences by infecting the urinary tract, blood-vessel, breasts, abscesses, bones, mucosal surfaces, and even devices implanted in the body. There is a sizeable number of people who carry MRSA but are not infected by it. MRSA, however, can create problems if it enters the body via cuts. Low immunity people are most likely to be afflicted with MRSA. Those working in healthcare institutes and those staying in closed communities, namely sports camps, prisons, and asylums are also highly susceptible to it. The hospital acquired MRSA (HA-MRSA) is most widespread due to large number of cases occurring in hospitals and healthcare centers.

Because of the limited number of treatments for the infection available so far, the MRSA drugs market holds out ample room for growth for existing and aspiring players. As a result, the market is seeing many new entrants and established ones focusing on product development. This is expected to have a positive impact on the trajectory of the market.

Based on regions, the global MRSA drugs market consists of five segments: Europe, North America, Latin America, Asia Pacific, and the Middle East and Africa. Of these, North America held the leading share with respect to revenue, mainly as a result of high infection rates of the disease, easy availability of drugs to treat it, and greater public awareness about the condition.

Pfizer, Inc., Debiopharm International, Paratek Pharmaceuticals, Actavis, Inc., are some of the prominent players in the global MRSA drugs market.

Request a Brochure of the Report @

Leave a Reply